NCT06105853 (A03) is a NA clinical trial of Trier Social Stress Test in Alcohol Use Disorder, sponsored by Central Institute of Mental Health, Mannheim.

Who is sponsoring NCT06105853?

NCT06105853 is sponsored by Central Institute of Mental Health, Mannheim.

What drugs are being tested in NCT06105853?

Interventions in NCT06105853: Trier Social Stress Test, Barlab Cue-Exposure, Functional magnetic resonance imaging.

What condition does NCT06105853 study?

NCT06105853 studies Alcohol Use Disorder, Stress Reaction, Social Stress, Craving, Relapse, Addiction, Alcohol, Risk Behavior.

Is NCT06105853 still recruiting?

NCT06105853 is currently recruiting now. Last updated 29 April 2025.

Last reviewed 2025-04-29 · How we verify

NCT06105853: A03

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neurobehavioral Profiles of Adaptive Stress Responses in Individuals With Alcohol Use Disorder

Recruiting now NA Last updated 29 April 2025

What this trial tests

NA trial testing Trier Social Stress Test in Alcohol Use Disorder in 100 participants. Currently enrolling.

Timeline

1 December 2023

Primary endpoint
30 June 2027

30 June 2027

Quick facts

Lead sponsor	Central Institute of Mental Health, Mannheim
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 December 2023
Primary completion	30 June 2027
Estimated completion	30 June 2027
Sites	2 locations across Germany

Drugs / interventions tested

Trier Social Stress Test
Barlab Cue-Exposure
Functional magnetic resonance imaging

Conditions studied

Alcohol Use Disorder — all drugs for Alcohol Use Disorder →
Stress Reaction — all drugs for Stress Reaction →
Social Stress — all drugs for Social Stress →
Craving — all drugs for Craving →

Sponsor

Central Institute of Mental Health, Mannheim

Who can join

Adults 18 to 65, any sex, with Alcohol Use Disorder or Stress Reaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to investigate longitudinal stress response profiles and adaptive versus non-adaptive stress responses in alcohol use disorder. The main questions the projects aims to answer are: What are the neurobehavioral underpinnings of adaptive stress responses and resilience to repeated stress exposure with regards to: * alcohol craving? * alcohol use? * their modulation by prior stress exposure, social interactions, coping strategies and individual health behavior? Participants will: * be exposed to an established experimental stress-induction protocol, the Trier Social Stress Test * be exposed to their favorite drink in a bar lab environment * be assessed using fMRI to determine their neural alcohol cue reactivity, response inhibition, and emotion processing * conduct an ambulatory phase to assess stressors, alcohol craving, substance use and details on social interactions, health behavior and coping strategies using ecological momentary assessment tools.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Trier Social Stress Test

Trials testing the same drug.

NCT04100213 — Real-Time Assessment of Stress and Stress Response · NA · withdrawn
NCT06977178 — Adverse Adolescent Pathways to Substance Use · NA · recruiting
NCT05795634 — Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease · NA · recruiting
NCT05570721 — Depression, Aging, Stress and Heart Health Study · NA · recruiting
NCT05992272 — Cue Effects in Human Addiction: Pavlovian to Instrumental Transfer · recruiting

Other recruiting trials for Alcohol Use Disorder

Currently open trials in the same condition.

NCT06860607 — Environment and Alcohol: A Pilot Study · Phase 1 · recruiting
NCT07325266 — Human Laboratory Study of Apremilast for Alcohol Use Disorder · Phase 2 · recruiting
NCT07046819 — Tirzepatide in MetALD · Phase 2 · recruiting
NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting
NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis · NA · recruiting

Other Central Institute of Mental Health, Mannheim trials

Trials by the same sponsor.

NCT06845124 — A Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Alcohol Craving in Patients With Alcohol Dependence · Phase 2 · recruiting
NCT00916201 — Evaluation Study of New Compounds With Potential Use in Schizophrenia · Phase 1 · withdrawn
NCT06959342 — Modification of Inhibitory Control and Craving Through Transcranial Direct Current Stimulation (tDCS) as an Add-On Treat · NA · recruiting
NCT06881810 — Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on to Psychosocial Treatment · Phase 2 · recruiting
NCT05726045 — Increasing Smoking Cessation Success Through Sleep-amplified Memory Consolidation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06105853 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Central Institute of Mental Health, Mannheim
Last refreshed: 29 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06105853.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing